Diabetes drugs like Ozempic lower cancer risks: Study

A category of diabetes drugs, which embrace the best-selling drug Ozempic, are related to a diminished danger of sure obesity-related cancers, based on a research launched Friday.

Revealed within the journal JAMA, the research in contrast sufferers with Kind 2 diabetes who have been handled with insulin versus sufferers who got a category of drug often called GLP-1 agonists, like Ozempic, between 2005 and 2018.

The researchers discovered that the sufferers who acquired GLP-1 agonists had a considerably decrease danger of creating 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.

Among the many cancers which noticed no vital change in danger have been thyroid most cancers and breast most cancers in postmenopausal ladies.

“Weight problems is well-known to be related to at the least 13 most cancers varieties,” research creator Rong Xu stated in an electronic mail to AFP.

“Our research gives proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu stated.

Among the many medication studied have been semaglutide—commercially offered as Ozempic—in addition to liraglutide and others. Ozempic was accepted in america in 2017.

GLP-1 agonists have been round for about 20 years, however a brand new era of those medication, amongst them Ozempic, has been popularized for his or her extra vital weight reduction results.

Xu steered that the protecting advantages demonstrated within the research could encourage medical doctors to prescribe GLP-1 therapies for diabetes sufferers as a substitute of different medicines like insulin.

© 2024 AFP